Ganetespib (STA-9090)

Name: Ganetespib (STA-9090)
Brand: Selleck Chemicals
SKU: S1159
Rating: 5 (23 reviews)

For research use only. Not for use in humans.

Catalog No.S1159

23 publications

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Selleck's Ganetespib (STA-9090) has been cited by 23 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 10.1038/nature21064

PubMed: 28178232 ( click the link to review the publication )

Cell, 2017, 168(5):856-866

PubMed: 28215707 ( click the link to review the publication )

Hepatology, 2019, 69(2):573-586

PubMed: 29356025 ( click the link to review the publication )

Nat Commun, 2019, 10(1):402

PubMed: 30679438 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 10.1530/ERC-18-0509

PubMed: 30730850 ( click the link to review the publication )

ACS Chem Neurosci, 2019, 10(6):2890-2902

PubMed: 31017387 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2019, 10:487

PubMed: 31379752 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.220871

PubMed: 31439673 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Mol Cell, 2018, 69(4):594-609

PubMed: 29452639 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Mol Cancer Res, 2018, 10.1158/1541-7786

PubMed: 30002191 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Nat Commun, 2017, 8(1):422

PubMed: 28871086 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1232

PubMed: 28450729 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Hum Mol Genet, 2015, 10.1093/hmg/ddv136

PubMed: 25877301 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1017

PubMed: 25297628 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(5):1015-22

PubMed: 25205430 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Targets

HSP90 ^[1]
(OSA 8 cells)

4 nM

In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. ^[1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. ^[1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. ^[2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. ^[3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.^[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. ^[4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HL60	MlTiRZBweHSxc3nzJGF{e2G7	NYT0Zpc6OzBxOECvNVUxNzJ3MDDuUS=>	M2nQXFI1NzR6L{eyJIg>		NVu1PHRocW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{	MoXSNlU5QDJ3NUC=
MV411	NHS4U5RCeG:ydH;zbZMhSXO\|YYm=	NHfBNJk{OC96MD:xOVAwOjVyIH7N	MkjKNlQwPDhxN{KgbC=>		NIK1NIZqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM>	NHy5SW4zPTh6MkW1NC=>
MGC-803	MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MnSzNE4yNTFyMECgcm0>	MmjaO\|IhcA>?		NXXyXIpIcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MWGyOVU6ODhyNR?=
SGC-7901	M{HaXmNmdGxiVnnhZoltcXS7IFHzd4F6	NXrUPFRwOC5zLUGwNFAhdk1?	NELOT\|Q4OiCq		M1fLZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MUeyOVU6ODhyNR?=
MKN-28	MkLIR4VtdCCYaXHibYxqfHliQYPzZZk>	NXXUZZBEOC5zLUGwNFAhdk1?	M{LNNlczKGh?		Mn3wbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NIHlUZczPTV7MEiwOS=>
MGC-803	NVG2S3RjTnWwY4Tpc44hSXO\|YYm=	NHPzcmwxNjFvMUCwNEBvVQ>?	NGrQUFQzPCCq		NXXIWIZDcW6mdXPld{BIOi:PIHPlcIwu[3mlbHWgZZJz\XO2	NXPRXYJWOjV3OUC4NFU>
HCT-116	MnTJSpVv[3Srb36gRZN{[Xl?	NVW2PXF6PTCwTR?=	NUnsU\|hXOjRiaB?=	NVXl[ZV1TE2VTx?=	MkOxbY5lfWOnZDDHNE9IOSCjcoLld5Q>	MknxNlUzOTB5OUS=
HT-29	MVvGeY5kfGmxbjDBd5NigQ>?	M2XjdFUxdk1?	MWCyOEBp	NYT1U2hqTE2VTx?=	NWfubVNJcW6mdXPl[EBIOC:JMTDhdpJme3R?	MoXENlUzOTB5OUS=
SCC25	MWLDfZRwgGmlaYT5JGF{e2G7	M{fqUFExNzVyIH7N	MXeyOEBp		M{D0U4Rm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	NX3RWWt6OjV{MEW0N\|A>
FUDA	NWrId3RwS3m2b4jpZ4l1gSCDc4PhfS=>	NGDybWEyOC93MDDuUS=>	MlnJNlQhcA>?		M1zrRYRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	NVnJOGhrOjV{MEW0N\|A>
Detroit562	MV\DfZRwgGmlaYT5JGF{e2G7	NYTQbZpOOTBxNUCgcm0>	NEHLSmMzPCCq		NIrq[Yxl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk>	MlHFNlUzODV2M{C=
CAL27	MkHqR5l1d3irY3n0fUBCe3OjeR?=	M4jHSFExNzVyIH7N	NF2wO20zPCCq		NVyw[Jg5\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6	NH3nTmYzPTJyNUSzNC=>
DSH1	NEWydHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPlTWM2OD14IH7N	MojlNlQ4QDR6M{m=
SW-1710	NFr4PJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfrTWM2OD14IH7N	MlfrNlQ4QDR6M{m=
T24	M1rVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nkfGlEPTB;NzDuUS=>	MXiyOFc5PDh\|OR?=
RT112	Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4WxT2lEPTB;OTDuUS=>	M3zhflI1Pzh2OEO5
639-V	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfmTWM2OD1zMDDuUS=>	NH3kcZEzPDd6NEizPS=>
SCaBER	NEjIZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXKTWM2OD1zMDDuUS=>	NUjDNYpwOjR5OES4N\|k>
BFTC	NE\EN\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTF5IH7N	M1jxNVI1Pzh2OEO5
J82	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPSUm14UUN3ME2xPEBvVQ>?	NE\tNW4zPDd6NEizPS=>
HT-1376	M4Pj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fVfWlEPTB;MkGgcm0>	NHHHRmIzPDd6NEizPS=>
647-V	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XENGlEPTB;Mkegcm0>	Mlj2NlQ4QDR6M{m=
UM-UC3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPh[GhsUUN3ME2zN{BvVQ>?	NY\hPYZUOjR5OES4N\|k>
LB831-BLC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\JTWlEPTB;M{Sgcm0>	NHLOOnEzPDd6NEizPS=>
KU-19-19	NEDUTZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTN4IH7N	MX6yOFc5PDh\|OR?=
35612	NVTUdWZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnlSWZYUUN3ME2zPEBvVQ>?	NUiyU5N3OjR5OES4N\|k>
5637	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTR2IH7N	M1jsNFI1Pzh2OEO5
HT-1197	NHjvbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTV\|IH7N	MkOzNlQ4QDR6M{m=
MGH-U3	M3rI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHqXpN3UUN3ME21N{BvVQ>?	M{O3UVI1Pzh2OEO5
TCCSUP	NHPpfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonTTWM2OD1zNEKgcm0>	NHz1bJMzPDd6NEizPS=>
RT4	NXfCdpZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4excmlEPTB;MUezN{BvVQ>?	MlvsNlQ4QDR6M{m=
SW780	NH7FcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYGzco1jUUN3ME2zOFUyKG6P	Mo\lNlQ4QDR6M{m=
RKO	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHS3eJpKSzVyPUSgcm0>	M4rzV\|I1Pjh{N{S3
LS-411 N	NYTYToRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWn4fIhwUUN3ME21JI5O	NYexVINWOjR4OEK3OFc>
SW620	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXQfXF7UUN3ME24JI5O	NFPzOW8zPDZ6Mke0Oy=>
HCT-15	NXvxb4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRThibl2=	M3jLS\|I1Pjh{N{S3
HuTu-80	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULuUnhKUUN3ME2xN{BvVQ>?	M2LKT\|I1Pjh{N{S3
HCT 116	MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLFb21QUUN3ME2xOEBvVQ>?	MlPINlQ3QDJ5NEe=
COLO-205	M3nxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILxenZKSzVyPUG0JI5O	MV[yOFY5Ojd2Nx?=
NCI-H747	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rhVmlEPTB;MUegcm0>	NF\oWXozPDZ6Mke0Oy=>
COLO-678	M{HXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPVToVZUUN3ME2yNUBvVQ>?	Ml73NlQ3QDJ5NEe=
LoVo	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHHTWM2OD1{MjDuUS=>	M1X4[\|I1Pjh{N{S3
LS-1034	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTNzIH7N	MVuyOFY5Ojd2Nx?=
SNU-C2B	M4LPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTR3IH7N	MlfvNlQ3QDJ5NEe=
LS-123	NX\3cpBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\5bWlEPTB;N{Ogcm0>	NFL4ZlQzPDZ6Mke0Oy=>
SK-CO-1	NGXpXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DXUmlEPTB;OEGgcm0>	M2DXZVI1Pjh{N{S3
HCC2998	MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTF{ODDuUS=>	MV:yOFY5Ojd2Nx?=
MDA-MB-231	M33jdGZ2dmO2aX;uJGF{e2G7	MkPCNVAxKG6P	Ml7tN\|AhdWmw		Mk[wbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIFjJSk0y\|rF?	MkXFNlQzPDh{NkW=
MDA-MB-435	MmDWSpVv[3Srb36gRZN{[Xl?	M{DOeFExOCCwTR?=	M{LxT\|MxKG2rbh?=		NW\HO2lycW6qaXLpeJMh[WOldX31cIF1cW:wIH;mJGhKTi1zzsG=	NWXaeFYyOjR{NEiyOlU>
BT-20	NXXKe3V7TnWwY4Tpc44hSXO\|YYm=	Mni4NVAxNzJ3MDDuUS=>	MmDkNlQhcA>?		NVG5UoRJemW\|dXz0[YQhcW5iYTDkc5NmNWSncHXu[IVvfCCmZYP0ZYJqdGm8YYTpc44hd2ZiRVfGVkwhUUeILVnSMEBOTVRuIHHu[EBEWkGI	NXv2cmpIOjRzN{O1OFE>
MDA-MB-231	NFryNVdHfW6ldHnvckBCe3OjeR?=	NGDvSmgyODBibl2=	M373SlI1KGh?		M1TMdolvcGmkaYTzJJRp\SCvaXfyZZRwenliYX7kJIlvfmG\|aY\lJINieGGlaYT5xsA>	MW[yOFE4OzV2MR?=
H82	MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfMfWpQUUN3ME2zNE4zPyCwTR?=	NXfMepJqOjRzNk[1NFU>
GLC4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTYTWM2OD1{MD60O{BvVQ>?	NFrPbXAzPDF4NkWwOS=>
H69	NV\aTW13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLqWVFKSzVyPUizMlM3KG6P	NWWxWlc6OjRzNk[1NFU>
H128	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknXTWM2OD14OT61OUBvVQ>?	MX2yOFE3PjVyNR?=
H146	NXHjflhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTJ6LkWxJI5O	M4jvTlI1OTZ4NUC1
H187	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\VTWM2OD1{ND65PUBvVQ>?	MYKyOFE3PjVyNR?=
H526	MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTJzLk[0JI5O	MXGyOFE3PjVyNR?=
N592	M3XFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3S4R2lEPTB;MUSuNVIhdk1?	NXfSNopHOjRzNk[1NFU>
H620	M4T5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;OUmlEPTB;M{KuOlchdk1?	NXzE[WlmOjRzNk[1NFU>
H792	NEG5b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTR3LkC3JI5O	Mmq1NlQyPjZ3MEW=
H1173	NVHhO3o6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHIOmRKSzVyPUGyMlYzKG6P	M4TYXFI1OTZ4NUC1
AC3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPITYFQUUN3ME2yOU46KG6P	MYiyOFE3PjVyNR?=
H82	MV\GeY5kfGmxbjDBd5NigQ>?	MnrnN\|Ahdk1?	MlK2O\|IhcA>?		NGP4dYtqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q>	MYeyOFE3PjVyNR?=
GLC4	MlHXSpVv[3Srb36gRZN{[Xl?	NF3PUXI{OCCwTR?=	MkjWO\|IhcA>?		M4i4[4lv\HWlZYOgdIVze2m\|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>	MXyyOFE3PjVyNR?=
H146	MUTGeY5kfGmxbjDBd5NigQ>?	Mk\oN\|Ahdk1?	MWq3NkBp		MYfpcoR2[2W\|IIDldpNqe3SnboSgS\|IwVSCyaHHz[UBienKnc4S=	NI\z[nMzPDF4NkWwOS=>
OVCAR-5	NXraXoc4S2WubDDWbYFjcWyrdImgRZN{[Xl?	NV\ZdYg5OC1zMECwJI5O	M1:2[\|czKGh?		MUfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NYnqVWJzOjN7MECxN\|Y>
OVCAR-8	NV\3dGFtS2WubDDWbYFjcWyrdImgRZN{[Xl?	MoX4NE0yODByIH7N	MWK3NkBp		MYTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MVeyN\|kxODF\|Nh?=
A1847	MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFvsOpYxNTFyMECgcm0>	NWX2XZZQPzJiaB?=		NFnuN\|JqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NGOzNIczOzlyMEGzOi=>
SKOV-3	NYXjWpZFS2WubDDWbYFjcWyrdImgRZN{[Xl?	MnLxNE0yODByIH7N	NYq2XG5NPzJiaB?=		NGLxNIpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NUmyOWNwOjN7MECxN\|Y>
OVCAR-5	MYTBdI9xfG:\|aYOgRZN{[Xl?	M1nqb\|ExNTFyMDDuUS=>	M37WcFI1NzR6L{eyJIg>		M2K3dYlv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm=	MoPCNlM6ODBzM{[=
OVCAR-8	Ml3oRZBweHSxc3nzJGF{e2G7	NG\4bFYyOC1zMECgcm0>	M{\YUVI1NzR6L{eyJIg>		M2DubIlv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm=	MljGNlM6ODBzM{[=
A1847	MkG4RZBweHSxc3nzJGF{e2G7	NGW4NJAyOC1zMECgcm0>	NHj2eJEzPC92OD:3NkBp		NHKxSFZqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5	NXfoWmNWOjN7MECxN\|Y>
H2228	MlPsR4VtdCCYaXHibYxqfHliQYPzZZk>	NWL2c\|U5OC1zMECwJI5O	MVy3NkBp		NWX2UHZFUUN3ME2xN{BvVQ>?	M4TJOlI{PTN\|Mk[1
H3122	NIfCeGlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYraWmRpOC1zMECwJI5O	NXzLSm5{PzJiaB?=		Mn76TWM2OD1zMDDuUS=>	M2H6XlI{PTN\|Mk[1
K008	MoXSR4VtdCCYaXHibYxqfHliQYPzZZk>				NVfOfGFqUUN3ME22NEBvVQ>?	MnvCNlM1OTh3MkO=
K028	M{TDOGNmdGxiVnnhZoltcXS7IFHzd4F6				MWnJR\|UxRTh2IH7N	MXmyN\|QyQDV{Mx?=
K029	NFvTTFhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?				M4DmRWlEPTB;NE[gcm0>	Ml3jNlM1OTh3MkO=
M23	MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				NFi4eHlKSzVyPUO3MlUhdk1?	MX[yN\|QyQDV{Mx?=
K033	Mlf0R4VtdCCYaXHibYxqfHliQYPzZZk>				NEHiTWVKSzVyPUe1MlUhdk1?	M4jlZ\|I{PDF6NUKz
K008	Mle1SpVv[3Srb36gRZN{[Xl?	M17QOVI2OCCwTR?=	NEm1b\|QzPCCq		MofCbY5lfWOnczDHNkBienKnc4S=	M2jFUlI{PDF6NUKz
K028	MmLpSpVv[3Srb36gRZN{[Xl?	MnroNlUxKG6P	MkXoNlQhcA>?		NH\RRYtqdmS3Y3XzJGczKGG{cnXzeC=>	MWCyN\|QyQDV{Mx?=
K029	MYDGeY5kfGmxbjDBd5NigQ>?	NEO3b2czPTBibl2=	M172PVI1KGh?		M2L3[Ilv\HWlZYOgS\|Eh[XK{ZYP0	NVfwZ\|c5OjN2MUi1NlM>
M23	NEXROXJHfW6ldHnvckBCe3OjeR?=	NE\mWHMzPTBibl2=	NXjRUmJOOjRiaB?=		MX7pcoR2[2W\|IFexJIFv\CCJMj;NJIFzemW\|dB?=	M33UbFI{PDF6NUKz
K033	NVnLOJZKTnWwY4Tpc44hSXO\|YYm=	NFO5[GYzPTBibl2=	MX:yOEBp		NU[xNXJOcW6mdXPld{BiKG2xZHXzeEBqdmO{ZXHz[UBqdiCJMTDwc5B2dGG2aX;u	Mm\UNlM1OTh3MkO=
K008	MljwRZBweHSxc3nzJGF{e2G7	MVuxNFAhdk1?	MlztO\|IhcA>?		NXvXVHJte2mpbnnmbYNidnSueTDpcoR2[2W\|IHHwc5B1d3Orcx?=	NFX0TowzOzRzOEWyNy=>
K028	MnTMRZBweHSxc3nzJGF{e2G7	MUCxNFAhdk1?	MYi3NkBp		Mn7Ed4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?	MkW0NlM1OTh3MkO=
K029	M4TzcGFxd3C2b4Ppd{BCe3OjeR?=	NXnLdYlUOTByIH7N	MlvxO\|IhcA>?		M2HmT5Nq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN?	MnH4NlM1OTh3MkO=
M23	M1PMXWFxd3C2b4Ppd{BCe3OjeR?=	NHK3VYcyODBibl2=	MVy3NkBp		NUfhXHFQe2mpbnnmbYNidnSueTDpcoR2[2W\|IHHwc5B1d3Orcx?=	NHHIUnczOzRzOEWyNy=>
K033	NE\NdJJCeG:ydH;zbZMhSXO\|YYm=	NEnGbHMyODBibl2=	M4\lTlczKGh?		MknSd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?	MVmyN\|QyQDV{Mx?=
RD	NFrZboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;ndpFKSzVyPUigcm0>	NXrzeVN6OjN\|MEO3OFE>
Rh41	MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVSwW25KUUN3ME2xNE41KG6P	NUHhW\|RIOjN\|MEO3OFE>
Rh18	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTZwMjDuUS=>	MknmNlM{ODN5NEG=
Rh30	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnWyTWM2OD13Lk[gcm0>	MV6yN\|MxOzd2MR?=
BT-12	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPpTWM2OD1zND6zJI5O	MoTiNlM{ODN5NEG=
CHLA-266	M1HRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHHc3dHUUN3ME2yO{4yKG6P	M3PXelI{OzB\|N{Sx
TC-71	NHHlfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTRwNTDuUS=>	NUjJ[Xg3OjN\|MEO3OFE>
CHLA-9	NU\TbJZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HIO2lEPTB;ND62JI5O	NEHDVoYzOzNyM{e0NS=>
CHLA-10	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDiOmJ4UUN3ME21Mlchdk1?	NGK0V5kzOzNyM{e0NS=>
CHLA-258	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDNeodVUUN3ME22MlQhdk1?	MXGyN\|MxOzd2MR?=
SJ-GBM2	M3G2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4roV2lEPTB;MUKuPUBvVQ>?	MW[yN\|MxOzd2MR?=
NB-1643	NHfHNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTdwNDDuUS=>	NYH1WlY2OjN\|MEO3OFE>
NB-EBc1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnaS4ptUUN3ME2xOk45KG6P	MV[yN\|MxOzd2MR?=
CHLA-90	NEPpZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJ{LkOgcm0>	Ml65NlM{ODN5NEG=
CHLA-136	NUX2Nms1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTJ\|LkKgcm0>	MUeyN\|MxOzd2MR?=
NALM-6	MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3UNZlZUUN3ME2xNU44KG6P	M4e0clI{OzB\|N{Sx
COG-LL-317	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLWTWM2OD12LkSgcm0>	M{\0S\|I{OzB\|N{Sx
RS4;11	NVvTfWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTF\|LkWgcm0>	M4HVOVI{OzB\|N{Sx
MOLT-4	M2LwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfwVG14UUN3ME2xNE43KG6P	MVKyN\|MxOzd2MR?=
CCRF-CEM (1)	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfETWM2OD1zMj61JI5O	MY[yN\|MxOzd2MR?=
CCRF-CEM (2)	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PFZmlEPTB;Nz6yJI5O	MnW2NlM{ODN5NEG=
Kasumi-1	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTVwODDuUS=>	NXqzO3NPOjN\|MEO3OFE>
Karpas-299	NF3mUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXH6[WR1UUN3ME25MlYhdk1?	NELsWHkzOzNyM{e0NS=>
Ramos-RA1	M4X1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\CTWM2OD15LkSgcm0>	NXLWc3NUOjN\|MEO3OFE>
LNCaP	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRThibl2=	NFGyOlIzOzF3MkCwOC=>
VCaP	NHziTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTdibl2=	NHru[lAzOzF3MkCwOC=>
H1355	NYHmR3pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7JbFRKSzVyPUWgcm0>	MUiyN\|AyOjJ2OB?=
H157	NIS1PG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jGR2lEPTB;NzDuUS=>	M1q5VVI{ODF{MkS4
H460	NGfZWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPwSI1jUUN3ME24JI5O	MVmyN\|AyOjJ2OB?=
IA-LM	M2HRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XUNWlEPTB;MUCgcm0>	Ml\JNlMxOTJ{NEi=
HOP-62	MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXDPG8{UUN3ME2xNUBvVQ>?	MWSyN\|AyOjJ2OB?=
H23	NH21eJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDGenBKSzVyPUGxJI5O	MWmyN\|AyOjJ2OB?=
H2030	NUe2c\|ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDKTWM2OD1zMjDuUS=>	MWSyN\|AyOjJ2OB?=
H441	NG\pXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D1fWlEPTB;MUSgcm0>	NYjP[ZR7OjNyMUKyOFg>
H2212	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjqSoRKSzVyPUG3JI5O	M1myc\|I{ODF{MkS4
SK-LU-1	NYW5dphtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXWwfpZzUUN3ME2xPEBvVQ>?	MWmyN\|AyOjJ2OB?=
H2009	NHrRV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmewTWM2OD1zOTDuUS=>	MlfxNlMxOTJ{NEi=
H1792	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkn6TWM2OD1{MDDuUS=>	M3[4UFI{ODF{MkS4
COR-L23	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7IepZDUUN3ME2yNkBvVQ>?	NWX2[opGOjNyMUKyOFg>
H727	NInoe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTJ6IH7N	NX;4e494OjNyMUKyOFg>
H1734	NWDJW5hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{W0WmlEPTB;Mkigcm0>	NVTke41TOjNyMUKyOFg>
H358	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHe0SnhKSzVyPUK5JI5O	NILVTI4zOzBzMkK0PC=>
A549	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jJcGlEPTB;NEOgcm0>	MYiyN\|AyOjJ2OB?=
H2122	MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjETWM2OD13MzDuUS=>	MonJNlMxOTJ{NEi=
Calu-1	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TYd2lEPTB;NUigcm0>	MWOyN\|AyOjJ2OB?=
Calu-6	NEPXd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTZ2IH7N	M2rLSFI{ODF{MkS4
NCI-H1975	NFHjdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3L3eFQ5KGh?		MWXJR\|UxRTF4IH7N	M{PFblIzOTR2Nk[1
NCI-H1975	MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFnEVHE4OiCq		NX7HPXNuUUN3ME24JI5O	M2\QblIzOTR2Nk[1

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK; PubMed: 23418523 PLoS One Downregulation of multiple signaling pathways by ganetespib in melanoma cells.A. Cells were treated with indicated amounts of ganetespib for 24 h. B-RAF and N-RAS mutational status of each cell line is indicated. p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4; PubMed: 23418523 PLoS One Alterations in expression of multiple cell cycle regulating proteins induced by ganetespib. Cells were treated with indicated amounts of ganetespib for 48 h and analyzed by Western blot analysis. Relative expression levels of proteins (treated vs. control䲧疝Ỵ疞㧀疜膉痘  Survivin / Bcl-2 / Bcl-xl / Mcl-1; PubMed: 23418523 PLoS One Effect of ganetespib on the expression of antiapoptotic proteins. Cells were treated with ganetespib for 48 h and analyzed using Western blot analysis. Relative expression levels of proteins are indicated. B-RAF / C-RAF / N-RAS ; PubMed: 23418523 PLoS One Effect of ganetespib on B-RAF, C-RAF and N-RAS expression in melanoma cells.Cells were treated with indicated amounts of ganetespib for 48 h and subjected to Western blot analysis. HER2 / p-STAT3 / BIM ; PubMed: 25077897 Target Oncol NCI-H1975 cells were incubated with the indicated concentrations of ganetespib for 24 h. Cell lysates were analyzed by Western blotting. CDK1 / Cyclin D1 / Cyclin B1 / p27; PubMed: 29717218 Sci Rep Cropped Western blot images of the indicated cell cycle regulators are shown in ganetespib-treated (0–300 nM for 16 hours) BT474 and SKBR3 cells. c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9; PubMed: 29717218 Sci Rep Cropped images of Western blots at the target molecular weights for the indicated apoptotic markers are shown in ganetespib-treated (0, 10, 30, 100, 300 nM for 16 hours) BT474 and SKBR3 cells. ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3; PubMed: 29717218 Sci Rep Ganetespib inhibits RTK signaling in ErbB2+ breast cancer cells. BT474 and SKBR3 cells were treated with ganetespib (0, 10, 30, 100, or 300 nM) for 16 hours, followed by Western blot analysis (cropped images) of the expression and activation/phosphorylati䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖 Wee1 / p-Wee1 / Chk1 / p-Chk1; PubMed: 27834954 Cell Death Differ Hsp90 inhibition degrades the G2/M checkpoint kinases Wee1 and Chk1. The cells were treated with 200 nM ganetespib and 75 μM carboplatin for 24 h followed by immunoblot analysis. Carboplatin treatment leads to the activation of Chk1, indicated by phospho—䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ	23418523 25077897 29717218 27834954
Growth inhibition assay	Cell viability ; PubMed: 23418523 PLoS One A. Ganetespib reduced viability. Cells were treated with varying amounts of ganetespib for 72 h and subjected to MTS assay. Data are expressed as mean±SD of three independent experiments. B. Mutational status and ganetespib IC50 of cell lines.	23418523

In vivo

Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.^[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: OSA cells
Concentrations: 0.001-1μM
Incubation Time: 5 days
Method: A total of 1.5 × 10³ OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female severe combined immune-deficient (SCID) mice
Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
Dosages: 25 mg/kg/day for 3 days
Administration: Tail vein injection
(Only for Reference)

References

[4] Lin TY, et al. Exp Hematol. 2008, 36(10), 1266-1277.

- Collapse

Solubility (25°C)

In vitro	DMSO	40 mg/mL (109.76 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ganetespib (STA-9090) SDF

Molecular Weight	364.4
Formula	C₂₀H₂₀N₄O₃
CAS No.	888216-25-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CC(C)C1=C(O)C=C(O)C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)[N](C)C=C4

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02192541	Terminated	Drug: Ziv-Aflibercept\|Drug: Ganetespib	Neoplasms	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	December 2 2014	Phase 1
NCT02008877	Completed	Drug: ganetespib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors (MPNST)\|Sarcoma	Sarcoma Alliance for Research through Collaboration\|Synta Pharmaceuticals Corp.\|United States Department of Defense	December 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does this inhibitor inhibit both isoforms of HSP90?
Answer:
We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Ganetespib (STA-9090)